Classification of endometrial carcinoma: More than two types

The Lancet Oncology

Volumn 15, Issue 7, 2014, Pages

  Murali, Rajmohan ^a   Soslow, Robert A ^a,b   Weigelt, Britta ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ARID1A GENE; CANCER CLASSIFICATION; CANCER GENETICS; CLINICAL FEATURE; DNA MODIFICATION; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; GENE; GENE MUTATION; GENE SEQUENCE; HISTOPATHOLOGY; HUMAN; KRAS GENE; PPP2R1A GENE; PRIORITY JOURNAL; PTEN GENE; REVIEW;

ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN PHOSPHATASE 2; PTEN PHOSPHOHYDROLASE;

EID: 84901423954     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(13)70591-6     Document Type: Review

References (85)

1. Siegel R, Naishadham D, Jemal A Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30.
2. Cancer Research UK Uterine cancer statistics (accessed Jan 23, 2014). http://info.cancerresearchuk.org/cancerstats/types/uterus/.
3. Wartko P, Sherman ME, Yang HP, Felix AS, Brinton LA, Trabert B Recent changes in endometrial cancer trends among menopausal-age U.S. women. Cancer Epidemiol 2013, 37:374-377.
4. Creasman WT, Odicino F, Maisonneuve P, et al. Carcinoma of the corpus uteri. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 2006, 95(suppl 1):S105-S143.
5. Bokhman JV Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983, 15:10-17.
6. Silverberg SG, Kurman RJ, Nogales F, Mutter GL, Kubik-Huch RA, Tavassoli FA Epithelial tumours and related lesions. World Health Organization classification of tumours: pathology and genetics-tumours of the breast and female genital organs 2003, 217-232. IARC Press, Lyon. F.A. Tavassoli, P. Devilee (Eds.).
7. Dedes KJ, Wetterskog D, Ashworth A, Kaye SB, Reis-Filho JS Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol 2011, 8:261-271.
8. Matias-Guiu X, Prat J Molecular pathology of endometrial carcinoma. Histopathology 2013, 62:111-123.
9. Salvesen HB, Haldorsen IS, Trovik J Markers for individualised therapy in endometrial carcinoma. Lancet Oncol 2012, 13:e353-e361.
10. Weigelt B, Banerjee S Molecular targets and targeted therapeutics in endometrial cancer. Curr Opin Oncol 2012, 24:554-563.
11. Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013, 497:67-73. for the Cancer Genome Atlas Research Network.
12. Kuhn E, Wu RC, Guan B, et al. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. J Natl Cancer Inst 2012, 104:1503-1513.
13. Lax SF, Kendall B, Tashiro H, Slebos RJ, Hedrick L The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 2000, 88:814-824.
14. Le Gallo M, O'Hara AJ, Rudd ML, et al. Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nat Genet 2012, 44:1310-1315. for the NIH Intramural Sequencing Center (NISC) Comparative Sequencing Program.
15. McConechy MK, Ding J, Cheang MC, et al. Use of mutation profiles to refine the classification of endometrial carcinomas. J Pathol 2012, 228:20-30.
16. Urick ME, Rudd ML, Godwin AK, Sgroi D, Merino M, Bell DW PIK3R1 (p85α) is somatically mutated at high frequency in primary endometrial cancer. Cancer Res 2011, 71:4061-4067.
17. Zhao S, Choi M, Overton JD, et al. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proc Natl Acad Sci USA 2013, 110:2916-2921.
18. Garg K, Broaddus RR, Soslow RA, Urbauer DL, Levine DA, Djordjevic B Pathologic scoring of PTEN immunohistochemistry in endometrial carcinoma is highly reproducible. Int J Gynecol Pathol 2012, 31:48-56.
19. Hoang LN, McConechy MK, Köbel M, et al. Histotype-genotype correlation in 36 high-grade endometrial carcinomas. Am J Surg Pathol 2013, 37:1421-1432.
20. Soslow RA High-grade endometrial carcinomas-strategies for typing. Histopathology 2013, 62:89-110.
21. Soslow RA, Wethington SL, Cesari M, et al. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma. Am J Surg Pathol 2012, 36:1771-1781.
22. Abu-Rustum NR, Zhou Q, Gomez JD, et al. A nomogram for predicting overall survival of women with endometrial cancer following primary therapy: toward improving individualized cancer care. Gynecol Oncol 2010, 116:399-403.
23. Cao QJ, Belbin T, Socci N, et al. Distinctive gene expression profiles by cDNA microarrays in endometrioid and serous carcinomas of the endometrium. Int J Gynecol Pathol 2004, 23:321-329.
24. Fles R, Hoogendoorn WE, Platteel I, et al. Genomic profile of endometrial tumors depends on morphological subtype, not on tamoxifen exposure. Genes Chromosomes Cancer 2010, 49:699-710.
25. Setiawan VW, Yang HP, Pike MC, et al. Type I and II endometrial cancers: have they different risk factors?. J Clin Oncol 2013, 31:2607-2618. the Australian National Endometrial Cancer Study Group.
26. Stefanick ML Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration. Am J Med 2005, 118(suppl 12B):64-73.
27. Kelly T, Yang W, Chen CS, Reynolds K, He J Global burden of obesity in 2005 and projections to 2030. Int J Obes (Lond) 2008, 32:1431-1437.
28. Garg K, Soslow RA Lynch syndrome (hereditary non-polyposis colorectal cancer) and endometrial carcinoma. J Clin Pathol 2009, 62:679-684.
29. Brinton LA, Felix AS, McMeekin DS, et al. Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial. Gynecol Oncol 2013, 129:277-284.
30. Voss MA, Ganesan R, Ludeman L, et al. Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation. Gynecol Oncol 2012, 124:15-20.
31. Soslow RA, Bissonnette JP, Wilton A, et al. Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: similar outcomes belie distinctive biologic differences. Am J Surg Pathol 2007, 31:979-987.
32. Zannoni GF, Scambia G, Gallo D The dualistic model of endometrial cancer: the challenge of classifying grade 3 endometrioid carcinoma. Gynecol Oncol 2012, 127:262-263.
33. Gilks CB, Oliva E, Soslow RA Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma. Am J Surg Pathol 2013, 37:874-881.
34. Garnett MJ, Edelman EJ, Heidorn SJ, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012, 483:570-575.
35. Podsypanina K, Ellenson LH, Nemes A, et al. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA 1999, 96:1563-1568.
36. Stambolic V, Tsao MS, Macpherson D, Suzuki A, Chapman WB, Mak TW High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice. Cancer Res 2000, 60:3605-3611.
37. Hayes MP, Wang H, Espinal-Witter R, et al. PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia. Clin Cancer Res 2006, 12:5932-5935.
38. Mutter GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000, 92:924-930.
39. Oda K, Stokoe D, Taketani Y, McCormick F High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 2005, 65:10669-10673.
40. Rudd ML, Price JC, Fogoros S, et al. A unique spectrum of somatic PIK3CA (p110α) mutations within primary endometrial carcinomas. Clin Cancer Res 2011, 17:1331-1340.
41. Cheung LW, Hennessy BT, Li J, et al. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov 2011, 1:170-185.
42. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004, 304:554.
43. Santin AD, Bellone S, Van Stedum S, et al. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma. Cancer 2005, 104:1391-1397.
44. ctn) expression in endometrial cancer and endometrial atypical hyperplasia. J Pathol 2003, 199:471-478.
45. Schlosshauer PW, Ellenson LH, Soslow RA β-catenin and E-cadherin expression patterns in high-grade endometrial carcinoma are associated with histological subtype. Mod Pathol 2002, 15:1032-1037.
46. Simpkins SB, Bocker T, Swisher EM, et al. MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers. Hum Mol Genet 1999, 8:661-666.
47. Salvesen HB, MacDonald N, Ryan A, et al. Methylation of hMLH1 in a population-based series of endometrial carcinomas. Clin Cancer Res 2000, 6:3607-3613.
48. Tashiro H, Isacson C, Levine R, Kurman RJ, Cho KR, Hedrick L p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 1997, 150:177-185.
49. Jia L, Liu Y, Yi X, et al. Endometrial glandular dysplasia with frequent p53 gene mutation: a genetic evidence supporting its precancer nature for endometrial serous carcinoma. Clin Cancer Res 2008, 14:2263-2269.
50. Wiegand KC, Lee AF, Al-Agha OM, et al. Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas. J Pathol 2011, 224:328-333.
51. Mao TL, Ardighieri L, Ayhan A, et al. Loss of ARID1A expression correlates with stages of tumor progression in uterine endometrioid carcinoma. Am J Surg Pathol 2013, 37:1342-1348.
52. Werner HM, Berg A, Wik E, et al. ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas. Mod Pathol 2013, 26:428-434.
53. McConechy MK, Anglesio MS, Kalloger SE, et al. Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas. J Pathol 2011, 223:567-573. for the Australian Ovarian Cancer Study Group.
54. Shih IM, Wang TL Mutation of PPP2R1A: a new clue in unveiling the pathogenesis of uterine serous carcinoma. J Pathol 2011, 224:1-4.
55. Liang H, Cheung LW, Li J, et al. Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer. Genome Res 2012, 22:2120-2129.
56. Gui Y, Guo G, Huang Y, et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet 2011, 43:875-878.
57. Heravi-Moussavi A, Anglesio MS, Cheng SW, et al. Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers. N Engl J Med 2012, 366:234-242.
58. Church DN, Briggs SE, Palles C, et al. DNA polymerase e and δ exonuclease domain mutations in endometrial cancer. Hum Mol Genet 2013, 22:2820-2828. the NSECG Collaborators.
59. Travis WD, Brambilla E, Riely GJ New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol 2013, 31:992-1001.
60. Pecorelli S Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 2009, 105:103-104.
61. Hayes DF, Bast RC, Desch CE, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996, 88:1456-1466.
62. McCluggage WG Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas. Int J Gynecol Cancer 2002, 12:687-690.
63. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012, 366:883-892.
64. Barlin JN, Zhou Q, St Clair CM, et al. Classification and regression tree (CART) analysis of endometrial carcinoma: seeing the forest for the trees. Gynecol Oncol 2013, 130:452-456.
65. Slomovitz BM, Coleman RL The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clin Cancer Res 2012, 18:5856-5864.
66. Forster MD, Dedes KJ, Sandhu S, et al. Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer. Nat Rev Clin Oncol 2011, 8:302-306.
67. Konecny GE, Kolarova T, O'Brien NA, et al. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells. Mol Cancer Ther 2013, 12:632-642.
68. Byron SA, Pollock PM FGFR2 as a molecular target in endometrial cancer. Future Oncol 2009, 5:27-32.
69. English DP, Roque DM, Santin AD HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies. Mol Diagn Ther 2013, 17:85-99.
70. Bose R, Kavuri SM, Searleman AC, et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov 2013, 3:224-237.
71. He L, Torres-Lockhart K, Forster N, et al. Mcl-1 and FBW7 control a dominant survival pathway underlying HDAC and Bcl-2 inhibitor synergy in squamous cell carcinoma. Cancer Discov 2013, 3:324-337.
72. Dedes KJ, Wetterskog D, Mendes-Pereira AM, et al. PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci Transl Med 2010, 2:53ra75.
73. Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013, 6:pl1.
74. Oza AM, Elit L, Tsao MS, et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol 2011, 29:3278-3285.
75. Trédan O, Treilleux I, Wang Q, et al. Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study. Target Oncol 2013, 8:243-251.
76. Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 2012, 338:221.
77. Ding L, Ellis MJ, Li S, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010, 464:999-1005.
78. Shah SP, Morin RD, Khattra J, et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009, 461:809-813.
79. Zannoni GF, Monterossi G, De Stefano I, et al. The expression ratios of estrogen receptor α (ERα) to estrogen receptor β1 (ERβ1) and ERα to ERβ2 identify poor clinical outcome in endometrioid endometrial cancer. Hum Pathol 2013, 44:1047-1054.
80. Huvila J, Talve L, Carpén O, et al. Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma. Gynecol Oncol 2013, 130:463-469.
81. Singh M, Zaino RJ, Filiaci VJ, Leslie KK Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 2007, 106:325-333.
82. Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 1999, 17:1736-1744.
83. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010, 28:2784-2795.
84. Kinde I, Bettegowda C, Wang Y, et al. Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med 2013, 5:167ra4.
85. Baselga J Bringing precision medicine to the clinic: from genomic profiling to the power of clinical observation. Ann Oncol 2013, 24:1956-1957.